Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (331-340 of 504) with videos related to

Pageof 51
Sort By:
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Oncotarget|July 9, 2016
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cellsZhihong Zeng, Rui-Yu Wang, Yi Hua Qiu, et al.
Leukemia & Lymphoma|January 18, 2018
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemiaPrajwal Boddu, Hagop Kantarjian, Farhad Ravandi, et al.
International Journal of Radiation Biology|January 27, 2016
Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cellsYoko Tabe, Yasuhito Hatanaka, Mayumi Nakashiro, et al.
Blood|July 3, 2025
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemiaBing Z Carter, Po Yee Mak, Edward Ayoub, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Cancer Research|March 2, 2018
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionJo Ishizawa, Kenji Nakamaru, Takahiko Seki, et al.
Molecular Cancer Therapeutics|April 1, 2022
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem CellsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
Pageof 51

Showing results (331-340 of 504) with videos related to

Sort By:
Pageof 51
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Oncotarget|July 9, 2016
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cellsZhihong Zeng, Rui-Yu Wang, Yi Hua Qiu, et al.
Leukemia & Lymphoma|January 18, 2018
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemiaPrajwal Boddu, Hagop Kantarjian, Farhad Ravandi, et al.
International Journal of Radiation Biology|January 27, 2016
Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cellsYoko Tabe, Yasuhito Hatanaka, Mayumi Nakashiro, et al.
Blood|July 3, 2025
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemiaBing Z Carter, Po Yee Mak, Edward Ayoub, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Cancer Research|March 2, 2018
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionJo Ishizawa, Kenji Nakamaru, Takahiko Seki, et al.
Molecular Cancer Therapeutics|April 1, 2022
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem CellsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
Pageof 51